BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:HPV vaccines - will they do their job? - Prof. Margaret Stanley\, 
 Dept. of Pathology\, University of Cambridge
DTSTART:20100126T120000Z
DTEND:20100126T130000Z
UID:TALK19365@talks.cam.ac.uk
CONTACT:Mala Jayasundera
DESCRIPTION:Viral infections cause at least 15% of all cancers\; one of th
 e most important oncogenic viruses is the human papillomavirus (HPV) a cau
 sal agent in 4% of all cancers.  The identification of the major oncogenic
  HPV’s HPV 16 and HPV 18 by Harald zur Hausen was recognised in 2008 by 
 the award to him of the Nobel Prize in Medicine.  The unfolding of the HPV
  story started in the 1970’s and has resulted in the development of prop
 hylactic vaccines using sophisticated recombinant molecular techniques and
  protein expression to prevent infection by HPV 16 and 18.  These vaccines
  are now licensed world wide and have been incorporated into national immu
 nisation programmes in several countries The vaccines are remarkably effic
 acious\, generate strong immunity and have a very good safety profile. Pro
 viding these vaccines are delivered as part of an organised immunisation p
 rogramme and achieve high coverage they should significantly reduce the in
 cidence of cervix cancer\, and other HPV associated cancers\, in the vacci
 nated cohort over the medium to long term.  However since the current vacc
 ines provide protection only against the 2 major oncogenic HPVs 16 and 18 
 that cause 70-80% of cervix cancers\, complete protection against HPV caus
 ed cervical cancer will require polyvalent vaccines or broadly protective 
 products in the future.  Recent data on the mechanism of viral entry and t
 he dynamics of the interaction of the viral capsid proteins L1 and L2 with
  the cell surface provide a rationale for the design of second generation 
 vaccines.
LOCATION:CRI Lecture Theatre
END:VEVENT
END:VCALENDAR